Patents Assigned to SOUTHERN MEDICAL UNIVERSITY
  • Publication number: 20210017189
    Abstract: Provided are 1,4-diphenyl-1H-imidazole and 2,4-diphenylthiazole derivatives having a structure represented by Formula I, a preparation method therefor and uses thereof: wherein R1 is any one of H, OH, and OCH3, R2 is any one of H, NO2, CH3, CF3, SO2CH3, COOCH3, or CONHCH3, R3 is any one of H, NO2, OCH3, or CF3, R4 is selected from H, CF3, or Cl, R5 is any one of H, Cl, CF3, or NHCH3, and R6 is any one of OCF3, CF3, or CN; V is either C or N, W is either CH or N, X is a C atom, Y is either CH or N, and Z is either CH or S. This compound can be used in preparation of anti-inflammatory adjuvants, TLR1 or TLR2 agonists, and anti-tumor agents and for regulating the activity activation level of TLR1 and TLR2 alkaline phosphatases in vitro and in vivo.
    Type: Application
    Filed: April 9, 2018
    Publication date: January 21, 2021
    Applicant: SOUTHERN MEDICAL UNIVERSITY
    Inventors: Kui CHENG, Shuwen LIU, Gengzhen ZHU
  • Publication number: 20200179430
    Abstract: P2Y1 receptor and an antagonist thereof are used in anti-depression and/or anti-anxiety disorder. It has been verified through experimental studies that the P2Y1 receptor can be used for screening for a medicine of anti-depression and/or anti-anxiety disorder, and also used for screening for depression and/or anxiety disorder, and for early warning of depression and/or anxiety disorder; and the antagonist of P2Y1 receptor has anti-depression and anti-anxiety effects which can be used to prepare a medicine of anti-depression and/or anti-anxiety disorder.
    Type: Application
    Filed: October 23, 2017
    Publication date: June 11, 2020
    Applicant: SOUTHERN MEDICAL UNIVERSITY
    Inventors: Tianming GAO, Qian WANG, Ying KONG, Dingyu WU, Jianming YANG
  • Publication number: 20190239495
    Abstract: A construction method for an immunodeficient rat model includes the following steps. The gRNAs targeted for knocking out a Prkdc gene and an IL2R? gene are mixed with CAS9 mRNA respectively, and frozen in RNase-free ultrapure water to obtain injections A and B correspondingly. A human SIRP? genomic DNA is amplified, purified, and frozen in RNase-free ultrapure water to obtain an injection C. The injections A and B are injected into cytoplasm of fertilized eggs of different rats, and the injection C is injected into a pronucleus of a fertilized egg of another rat. The three fertilized eggs are then transplanted into different pseudo-pregnant female rats to breed second-generation rats A, B and C, respectively. The second-generation rats A, B and C are intercrossed to breed an F1 generation; and the F1 generation is further intercrossed to obtain IL2R? and Prkdc gene knockout immunodeficient rat models with human SIRP? gene.
    Type: Application
    Filed: March 27, 2017
    Publication date: August 8, 2019
    Applicants: SOUTHERN MEDICAL UNIVERSITY, GUANGDONG SHENGSAI BIOTECHNOLOGY CO., LTD
    Inventor: Yang XU
  • Patent number: 10352857
    Abstract: The present invention provides use of penta-substituted tetrahydropyrimidines in preparation of thermo-sensitive fluorescent materials. Said penta-substituted tetrahydropyrimidine compounds have linear temperature dependence of red-edge excitation wavelength (LTDREEW). When different excitation wavelengths are chosen, such compounds present fluorescence color and/or fluorescence on-off switch in different temperature ranges. Also their fluorescence intensity ratios or fluorescence intensities exhibit good linear relation or power function relation to temperature, which can be used as the thermo-sensitive fluorescent materials with high sensitivity and wide temperature range (0-450 K).
    Type: Grant
    Filed: April 5, 2016
    Date of Patent: July 16, 2019
    Assignee: SOUTHERN MEDICAL UNIVERSITY
    Inventor: Qiuhua Zhu
  • Patent number: 10260114
    Abstract: The present invention relates in a first aspect to a method of preparing a crystalline lanthanum-carboxylate coordination polymer and the crystalline lanthanum-carboxylate coordination polymer obtained or obtainable by the method. In another aspect of the present invention, also provides a method of detecting a target nucleic acid sequence in a sample.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: April 16, 2019
    Assignees: MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY, SOUTHERN MEDICAL UNIVERSITY
    Inventors: Jin-Xiang Chen, Bin Sun, Bao-Ping Xie, Zhi-Hong Jiang, Li-Ping Bai
  • Patent number: 10188357
    Abstract: A support unit (200), a support device (100) and an emission tomography device using the support device (100) are provided. The support unit (200) comprises: a support body (210), in which an accommodation space (220) that penetrates through the support body is provided, comprising multiple support positions (230A, 230B) that are distributed along a circumferential direction of the accommodation space (220); and multiple fastening means (240A, 240B), connected to at least some of the multiple support positions. At least some of the multiple fastening means (240A, 240B) can move between a contraction position and an extension position along a radial direction of the accommodation space (220). The fastening means (240A, 240B) are used to fasten detectors of the emission tomography device.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: January 29, 2019
    Assignee: DONGGUAN SONGSHAN LAKE SOUTHERN MEDICAL UNIVERSITY SCI. & TECH. PARK CO., LTD.
    Inventors: Han Shi, Jianfeng Xu, Qiyu Peng
  • Patent number: 10023594
    Abstract: A method of preparing a crystalline zwitterionic zinc(II)-carboxylate compound includes the steps of preparing a mixture of zinc(II) ions and a first pyridyl ligand having three carboxylic acid moieties; subjecting the mixture to conditions under which a precipitate is formed; separating the precipitate; adding a solvent and optionally a second pyridyl ligand to the separated precipitate; subjecting the obtained mixture to conditions under which crystals of the zwitterionic zinc(II)-carboxylate compound are formed; and separating the crystals of the zwitterionic zinc(II)-carboxylate compound. Preferably but not exclusively, the crystalline zwitterionic zinc(II)-carboxylate compound essentially consists of at least one 1D coordination polymer.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: July 17, 2018
    Assignees: MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY, SOUTHERN MEDICAL UNIVERSITY
    Inventors: Jin-Xiang Chen, Bin Sun, Hai-Qing Zhao, Bao-Ping Xie, Li-Ping Bai, Zhi-Hong Jiang
  • Patent number: 9828412
    Abstract: The present invention discloses a short peptide targeting EPS8 binding with EGFR and use thereof, and sequence of the short peptide is N?-Arg-Lys-Lys-Asn-Lys-Pro-Pro-Pro-Pro-Lys-Lys-C?. The short peptide can effectively inhibit proliferation of EPS8 positive tumors, and can also be used to make a pharmaceutical preparation for treating EPS8 positive tumors, which has the potential of being developed into anti-cancer peptide inhibitor drugs.
    Type: Grant
    Filed: December 25, 2014
    Date of Patent: November 28, 2017
    Assignee: SOUTHERN MEDICAL UNIVERSITY
    Inventors: Yu Hua Li, Tong Yuan Xue
  • Publication number: 20170303871
    Abstract: A support unit (200), a support device (100) and an emission tomography device using the support device (100) are provided. The support unit (200) comprises: a support body (210), in which an accommodation space (220) that penetrates through the support body is provided, comprising multiple support positions (230A, 230B) that are distributed along a circumferential direction of the accommodation space (220); and multiple fastening means (240A, 240B), connected to at least some of the multiple support positions. At least some of the multiple fastening means (240A, 240B) can move between a contraction position and an extension position along a radial direction of the accommodation space (220). The fastening means (240A, 240B) are used to fasten detectors of the emission tomography device.
    Type: Application
    Filed: November 6, 2015
    Publication date: October 26, 2017
    Applicant: DONGGUAN SONGSHAN LAKE SOUTHERN MEDICAL UNIVERSITY SCI. & TECH. PARK CO., LTD.
    Inventors: Han Shi, Jianfeng Xu, Qiyu Peng
  • Publication number: 20170307527
    Abstract: The present invention provides use of penta-substituted tetrahydropyrimidines in preparation of thermo-sensitive fluorescent materials. Said penta-substituted tetrahydropyrimidine compounds have linear temperature dependence of red-edge excitation wavelength (LTDREEW). When different excitation wavelengths are chosen, such compounds present fluorescence color and/or fluorescence intensity on-off switching in different temperature ranges. Also their fluorescence intensity ratios or fluorescence intensities exhibit good linear relation or power function relation to temperature, which can be used as the thermo-sensitive fluorescent materials with high sensitivity and wide temperature range (0-450 K).
    Type: Application
    Filed: April 5, 2016
    Publication date: October 26, 2017
    Applicant: SOUTHERN MEDICAL UNIVERSITY
    Inventor: Qiuhua ZHU
  • Publication number: 20160145302
    Abstract: The present invention discloses a short peptide targeting EPS8 binding with EGFR and use thereof, and sequence of the short peptide is N?-Arg-Lys-Lys-Asn-Lys-Pro-Pro-Pro-Pro-Lys-Lys-C?. The short peptide can effectively inhibit proliferation of EPS8 positive tumors, and can also be used to make a pharmaceutical preparation for treating EPS8 positive tumors, which has the potential of being developed into anti-cancer peptide inhibitor drugs.
    Type: Application
    Filed: December 25, 2014
    Publication date: May 26, 2016
    Applicant: SOUTHERN MEDICAL UNIVERSITY
    Inventors: Yu Hua LI, Tong Yuan XUE
  • Patent number: 9139502
    Abstract: The invention relates to a use of an urushiol compound (code named GQ-5) in preparation of pharmaceutical compositions for inhibiting Smad3 phosphorylation. We verify that GQ-5 inhibited the interaction of Smad3 with TGF-? type I receptor (T?RI), inhibited subsequent phosphorylation of Smad3, reduced nuclear translocation of Smads complex, and suppressed the transcription of major fibrotic genes such as ?-smooth muscle actin (?-SMA), collagen I and fibronectin. Therefore, GQ-5 could be a potent and selective inhibitor of TGF-?1-induced Smad3 phosphorylation, and be used to prepare pharmaceutical compositions for inhibiting Smad3 phosphorylation.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: September 22, 2015
    Assignees: SOUTHERN HOSPITAL, SOUTHERN MEDICAL UNIVERSITY, KUNMING INSTITUTE OF BOTANY, CHINESE ACADEMY OF SCIENCES
    Inventors: Fan Fan Hou, Yongxian Cheng, Jing Nie, Jun Al, Jiangbo He
  • Publication number: 20150175511
    Abstract: The invention relates to a use of an urushiol compound (code named GQ-5) in preparation of pharmaceutical compositions for inhibiting Smad3 phosphorylation. We verify that GQ-5 inhibited the interaction of Smad3 with TGF-? type I receptor (T?RI), inhibited subsequent phosphorylation of Smad3, reduced nuclear translocation of Smads complex, and suppressed the transcription of major fibrotic genes such as ?-smooth muscle actin (?-SMA), collagen I and fibronectin. Therefore, GQ-5 could be a potent and selective inhibitor of TGF-?1-induced Smad3 phosphorylation, and be used to prepare pharmaceutical compositions for inhibiting Smad3 phosphorylation.
    Type: Application
    Filed: November 3, 2014
    Publication date: June 25, 2015
    Applicants: SOUTHERN HOSPITAL, SOUTHERN MEDICAL UNIVERSITY, Kunming Institute of Botany, Chinese Academy of Sciences
    Inventors: Fan Fan HOU, Yongxian CHENG, Jing NIE, Jun AI, Jiangbo HE
  • Patent number: 8906927
    Abstract: The present invention provides a series of penta-substituted tetrahydropyrimidines with aggregation-induced emission (AIE) characteristics and preparation method and use thereof. The AIE penta-substituted tetrahydropyrimidines have structures shown as formula (I). R1 is selected from a group consisting of linear or branched alkyls and substituted alkyls. R2 and R4 is respectively selected from a group consisting of linear or branched alkyls, substituted alkyls, cycloalkyls, substituted cycloalkyls, aryls, substituted aryls, polycyclic aryls, substituted polycyclic aryls, heterocyclyls, substituted heterocyclyls, aromatic heterocyclyls and substituted aromatic heterocyclyls. R3 is selected from a group consisting of aryls, substituted aryls, polycyclic aryls, substituted polycyclic aryls, aromatic heterocyclyls and substituted aromatic heterocyclyls. The penta-substituted tetrahydropyrimidines can be prepared by multi-component reactions (MCR).
    Type: Grant
    Filed: December 24, 2011
    Date of Patent: December 9, 2014
    Assignee: Southern Medical University
    Inventors: Qiuhua Zhu, Shuwen Liu
  • Publication number: 20140051855
    Abstract: The present invention provides a series of penta-substituted tetrahydropyrimidines with aggregation-induced emission (AIE) characteristics and preparation method and use thereof. The AIE penta-substituted tetrahydropyrimidines have structures shown as formula (I). R1 is selected from a group consisting of linear or branched alkyls and substituted alkyls. R2 and R4 is respectively selected from a group consisting of linear or branched alkyls, substituted alkyls, cycloalkyls, substituted cycloalkyls, aryls, substituted aryls, polycyclic aryls, substituted polycyclic aryls, heterocyclyls, substituted heterocyclyls, aromatic heterocyclyls and substituted aromatic heterocyclyls. R3 is selected from a group consisting of aryls, substituted aryls, polycyclic aryls, substituted polycyclic aryls, aromatic heterocyclyls and substituted aromatic heterocyclyls. The penta-substituted tetrahydropyrimidines can be prepared by multi-component reactions (MCR).
    Type: Application
    Filed: December 24, 2011
    Publication date: February 20, 2014
    Applicant: SOUTHERN MEDICAL UNIVERSITY
    Inventors: Qiuhua Zhu, Shuwen Liu